• PMS51 GABAPENTIN, OPIOID, AND BENZODIAZEPINE PRESCRIBING IN EARLY CARE OF INDIVIDUALS WITH CHRONIC BACK PAIN: A SECULAR TRENDS ANALYSIS

    May 1, 2020, 00:00
  • PCV60 PREVALENCE, RISK FACTORS, AND MANAGEMENT OF UNCONTROLLED HYPERTENSION AMONG DIABETIC PATIENTS: A HOSPITAL-BASED CROSS-SECTIONAL STUDY

    May 1, 2020, 00:00
  • PDB66 DEFINING DIABETES MELLITUS USING ADMINISTRATIVE CLAIMS DATA

    May 1, 2020, 00:00
  • PDB55 ANNUAL HEALTH INSURANCE TREATMENT COST OF NON-INSULIN-DEPENDENT DIABETES WITH MULTIPLE COMPLICATIONS BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00
  • PDB73 EPIDEMIOLOGICAL DISEASE BURDEN OF DIABETIC POLYNEUROPATHY BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00
  • PCV78 ASSESSMENT OF HEALTH LITERACY AND THERAPEUTIC ADHERENCE AMONG PATIENTS WITH HYPERTENSION

    May 1, 2020, 00:00
  • PBI17 BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

    May 1, 2020, 00:00
  • PMH70 OVERVIEW OF INDIVIDUALS WITH ANXIETY DISORDERS IN THE U.S. AND TREATMENT PATTERNS IN ANTI-ANXIETY MEDICATION REGIMENS.

    May 1, 2020, 00:00
  • PDG46 OUTPATIENT OFF-LABEL GABAPENTIN UTILIZATION FROM 2011 TO 2015 AMONG UNITED STATES ADULTS

    May 1, 2020, 00:00
  • PMH10 DETERMINANTS, TRENDS, AND COSTS ASSOCIATED WITH 30-DAY ALL-CAUSE READMISSION IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH SUICIDAL IDEATION USING THE NATIONWIDE READMISSION DATABASE

    May 1, 2020, 00:00
  • PMU30 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING FOR SPINAL MUSCULAR ATROPHY (SMA) IN THE UNITED STATES

    May 1, 2020, 00:00
  • PMU43 ASSOCIATION BETWEEN ATOPIC DISEASES AND ANEMIA IN KOREAN PATIENTS

    May 1, 2020, 00:00
  • AI4 CAN WE DECREASE THE SCREENING BURDEN IN SYSTEMATIC REVIEWS? PERFORMANCE OF TWO NATURAL LANGUAGE PROCESSORS TO EXCLUDE RECORDS

    May 1, 2020, 00:00
  • PIH7 ANNUAL HEALTH INSURANCE TREATMENT COST OF CERVICAL CANCER BASED ON ROUTINELY COLLECTED NATIONWIDE REAL-WORLD FINANCING DATA IN HUNGARY

    May 1, 2020, 00:00
  • PDG50 COMMUNICATION BETWEEN PATIENTS AND HEALTH CARE PROFESSIONALS ABOUT OPIOID MEDICATIONS: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00
  • PBI18 BIOLOGIC THERAPIES FOR MODERATE-TO-SEVERE PSORIASIS: COST PER RESPONDER ANALYSIS CONSIDERING PRIVATE HEALTHCARE SYSTEM IN BRAZIL

    May 1, 2020, 00:00
  • PDB26 ESTIMATED RENAL AND CARDIOVASCULAR OUTCOMES AND COST OFFSETS IN PATIENTS WITH TYPE 2 DIABETES (T2D) AND DIABETIC NEPHROPATHY (DKD) TREATED WITH CANAGLIFLOZIN

    May 1, 2020, 00:00
  • PCV75 IDENTIFYING APPROPIATE HOSPITALS FOR PATIENT RECRUITMENT IN CLINICAL TRIALS FOR CANADA USING MACHINE LEARNING ALGORITHMS

    May 1, 2020, 00:00
  • PIN5 PREVALENCE OF DRUG RESISTANCE IN NUCLEOSIDE/NUCLEOTIDE ANALOGUE-TREATED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS B VIRUS

    May 1, 2020, 00:00
  • Alternative Medicine Public Health

    May 1, 2020, 00:00
  • PCV84 BASELINE CHARACTERISTICS OF HEARTH FAILURE PATIENTS IN A PRIVATE PROVIDER IN CHILE

    May 1, 2020, 00:00
  • PIH37 INEQUALITY OF OPPORTUNITY IN MATERNAL HEALTH AMONG ADOLESCENTS

    May 1, 2020, 00:00
  • PMH24 BUDGET IMPACT ANALYSIS OF VORTIOXETINE AND/OR SERTRALINE USE FOR MANAGEMENT OF MAJOR DEPRESSIVE DISORDER IN THE KINGDOM OF SAUDI ARABIA

    May 1, 2020, 00:00
  • PIH66 ASSOCIATION BETWEEN MEDICATION BURDEN AND ADHD MEDICATION ADHERENCE IN A PEDIATRIC POPULATION WITH MULTIPLE CHRONIC CONDITIONS

    May 1, 2020, 00:00
  • PDB63 MULTIMORBIDTY AND FIVE-YEAR TREND IN DIABETES CARE MANAGEMENT (DCM) AMONG ADULTS WITH DIABETES

    May 1, 2020, 00:00
  • Diabetes/Endocrine/Metabolic Disorders - Patient-Centered Research

    May 1, 2020, 00:00
  • Diabetes/Endocrine/Metabolic Disorders - Economic Evaluation

    May 1, 2020, 00:00
  • PIH72 PRENATAL MATERNAL STRESS CAN BE REDUCED BY MINDFULNESS TRAINING

    May 1, 2020, 00:00
  • Medical Devices - Epidemiology Public Health

    May 1, 2020, 00:00
  • PIN76 CHARACTERISTICS OF PATIENTS WITH CHRONIC HEPATITIS C TREATED UNDER A NEW STANDARD OF CARE

    May 1, 2020, 00:00
  • PIN51 FACTORS ASSOCIATED WITH INCREASED RISK OF HERPES ZOSTER AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    May 1, 2020, 00:00
  • PIH59 ADHERENCE TO TREATMENT FOR POLYCYSTIC OVARIAN SYNDROME: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00
  • PIN34 COST-UTILITY ANALYSIS OF DIRECT ACTING ANTIVIRALS FOR EARLY-STAGE GENOTYPE 1 HCV PATIENTS IN BRAZIL

    May 1, 2020, 00:00
  • PMH40 TRENDS IN ATYPICAL ANTIPSYCHOTIC MEDICATION USE IN US ADULTS

    May 1, 2020, 00:00
  • PDB14 HYPOTHERMICALLY STORED HUMAN AMNIOTIC MEMBRANE (HSAM) FOR THE MANAGEMENT OF DIABETIC FOOT ULCERS

    May 1, 2020, 00:00
  • PDB46 ELEVATED ANNUAL HEALTHCARE UTILIZATION AND DIRECT MEDICAL COSTS ASSOCIATED WITH DIABETES MELLITUS PATIENTS WITH OSTEOPOROSIS IN CHINA

    May 1, 2020, 00:00
  • PMS62 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE WRIST AND HAND BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00
  • PMS65 A VISUAL ANALYTICAL APPROACH TO UNDERSTANDING TREATMENT PATTERNS AMONG TREATMENT-NAÏVE RHEUMATOID ARTHRITIS PATIENTS WITH BIOLOGIC USE IN THE US VETERANS HEALTH ADMINISTRATION DATABASE

    May 1, 2020, 00:00
  • PDB99 BASELINE CHARACTERISTICS OF ENDOMETRIOSIS PATIENTS PARTICIPATING IN A REAL WORLD PROSPECTIVE COHORT STUDY: AN INTERIM ANALYSIS OF THE ELAGOLIX LONGITUDINAL OUTCOMES (LOTUS) STUDY

    May 1, 2020, 00:00
  • PDB11 THE PERINATAL OUTCOMES AMONG WOMEN WITH TWIN PREGNANCIES: PROPENSITY SCORE MATCHED ANALYSIS FROM A SEVEN-YEAR RETROSPECTIVE COHORT

    May 1, 2020, 00:00
  • PMU50 CHARACTERIZATION AND TRENDS OF MATERNAL MORTALITY IN TWO TERTIARY HOSPITALS IN NIGERIA: WHY DID THEY DIE?

    May 1, 2020, 00:00
  • Cardiovascular Disorders - Real World Data Information Systems

    May 1, 2020, 00:00
  • PMD24 ANALYSIS OF THE COST-EFFECTIVENESS OF THE LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM AS ALTERNATIVE TO HISTERECTOMIES IN PRIVATE HEALTH INSURANCE IN BRAZIL

    May 1, 2020, 00:00
  • PMH59 COMPLEX EXAMINATION OF THE MENTAL HEALTH OF TEACHERS

    May 1, 2020, 00:00
  • PDG51 PREVALENCE AND RELATIVE PREDICTIVE VALUE OF DEMOGRAPHIC AND PAIN CHARACTERISTICS FOR OPIOID USE AMONG A NATIONAL SAMPLE OF COMMUNITY-BASED OLDER ADULTS WITH PAIN IN THE UNITED STATES

    May 1, 2020, 00:00
  • PCV57 THE BURDEN OF HEART FAILURE IN NORTH AMERICA AND WESTERN EUROPE

    May 1, 2020, 00:00
  • PIH45 COST-EFFECTIVENESS OF A CARE PUBLIC PROGRAM FOR PREGNANT WOMEN WHO HAD THEIR DELIVERY IN A THIRD - LEVEL - COMPLEXITY HOSPITAL AT COLOMBIA

    May 1, 2020, 00:00
  • PMH67 CAPTURING PATIENT EXPERIENCE AS A KEY TO BETTER OUTCOMES: THE IMPORTANCE OF COGNITIVE APPRAISAL PROCESSES IN ENABLING RESILIENCE AMONG DEPRESSED INDIVIDUALS

    May 1, 2020, 00:00
  • PMS75 PATIENT- AND PHYSICIAN-IDENTIFIED FACTORS GUIDING TREATMENT CHOICE IN KNEE OSTEOARTHRITIS AND PATIENT PREFERENCE FOR INTRA-ARTICULAR THERAPY

    May 1, 2020, 00:00
  • Infectious Diseases - Real World Data Information Systems

    May 1, 2020, 00:00
  • PDB9 THE COMPARATIVE EFFICACY OF ORAL SEMAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA)

    May 1, 2020, 00:00
  • PMU28 CLINICAL AND ECONOMIC OUTCOMES OF CARBAPENEM-RESISTANT GRAM-NEGATIVE ORGANISMS: A MULTICENTER STUDY IN CHINA

    May 1, 2020, 00:00
  • PMD34 DEEP JOINT INFECTION COMPARISON BETWEEN SIMULTANEOUS AND STAGED BILATERAL TOTAL KNEE ARTHROPLASTY

    May 1, 2020, 00:00
  • Competing Views on the English EQ-5D-5L Valuation Set [Editor's Choice]

    May 1, 2020, 00:00
  • Drugs Regulatory

    May 1, 2020, 00:00
  • PMH45 DISPARITIES IN TREATMENT ADMISSIONS FOR OPIOID USE DISORDER IN CINCINNATI BY RACE

    May 1, 2020, 00:00
  • Methods for Moving the Evaluation of Precision Medicine Into Practice and Policy

    May 1, 2020, 00:00
  • PIN87 PATIENT ENGAGEMENT IN HIV CARE MANAGEMENT: BEHAVIOR ECONOMICS OF ART ADHERENCE AND ESTABLISHING CARE VISITS

    May 1, 2020, 00:00
  • PDB104 OPTIMIZATION OF INSULIN DOSE IN HOSPITALIZED PATIENTS WITH RECURRENT HYPOGLYCEMIA: REAL WORLD EXPERIENCE

    May 1, 2020, 00:00
  • PCV64 IMPACT ON ANTIHYPERTENSIVE PRESCRIBING AFTER THE DEAR HEALTHCARE PROFESSIONAL LETTER ON INCREASED RISK OF SKIN CANCER RELATED TO HYDROCHLOROTHIAZIDE

    May 1, 2020, 00:00
  • PDB107 ASSESSING ASYMMETRICAL PRESCRIBING OF ANTIDIABETIC DRUGS RELATIVE TO DIAGNOSIS OF NAFLD

    May 1, 2020, 00:00
  • PIH43 SEXUAL BEHAVIOR, USE OF CONTRACEPTIVE METHODS AND PREGNANCY IN YOUNG PEOPLE FROM A POPULATION AFFILIATED IN A HEALTH INSURER COMPANY IN COLOMBIA 2018

    May 1, 2020, 00:00
  • PMS57 EPIDEMIOLOGIC MODELING TO GUIDE PAYER DECISIONS IN RARE DISEASES: A CASE STUDY OF DUCHENNE MUSCULAR DYSTROPHY IN THE UNITED STATES

    May 1, 2020, 00:00
  • PMD47 THE CHOICES COMPARATIVE TRIAL: FACILITY COST AND OUTCOMES ANALYSIS OF MYOMECTOMY COMPARED TO TREATMENT WITH THE SONATA SYSTEM

    May 1, 2020, 00:00
  • PMS61 DISABILITY AND DEPRESSION IN LOW BACK PAIN. EVIDENCE FROM A COHORT STUDY

    May 1, 2020, 00:00
  • PMH63 HUMANISTIC BURDEN ASSOCIATED WITH MAJOR DEPRESSIVE DISORDER AND GLOBAL ANXIETY DISORDER AMONG ADULTS WITH NON-COMMUNICABLE DISEASES (NCCDS) IN THE UNITED STATES

    May 1, 2020, 00:00
  • PIH53 PHARMACISTS' INTERVENTIONS IN TRANSITIONS OF CARE: EVALUATING THE FINANCIAL AND CLINICAL IMPLICATIONS FOR LONG-TERM CARE

    May 1, 2020, 00:00
  • PIH69 THE NEED FOR PERSON-CENTRED CARE IN ENDOMETRIOSIS TREATMENT: QUALITATIVE INSIGHTS AND DISCRETE CHOICE EXPERIMENT DEVELOPMENT

    May 1, 2020, 00:00
  • Mental Health - Economic Evaluation

    May 1, 2020, 00:00
  • Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling Effects

    May 1, 2020, 00:00
  • PIN70 COST OF BLOOD AND BODY FLUID OCCUPATIONAL EXPOSURE MANAGEMENT IN CHINA

    May 1, 2020, 00:00
  • PMU52 CLINICAL ADOPTION OF GENOMIC TESTING IN ONCOLOGY: A TARGETED LITERATURE REVIEW OF THE GLOBAL PAYER LANDSCAPE

    May 1, 2020, 00:00
  • PDB75 EFFECT OF CHRONIC EXPOSURE TO PSYCHOTROPIC MEDICATION ON THE INCIDENCE OF NEW-ONSET TYPE 2 DIABETES MELLITUS IN ADULTS, A RETROSPECTIVE COHORT STUDY USING PRESCRIPTION CLAIMS FROM COLOMBIA

    May 1, 2020, 00:00
  • PMD15 ASSESSMENT OF THE RISK AND ECONOMIC BURDEN OF SURGICAL SITE INFECTION FOLLOWING COLORECTAL SURGERY USING A US LONGITUDINAL DATABASE: IS THERE A ROLE FOR INNOVATIVE ANTIMICROBIAL WOUND CLOSURE TECHNOLOGY TO REDUCE THE RISK OF INFECTION ...

    May 1, 2020, 00:00
  • Quantifying Downstream Healthcare Utilization in Studies of Genomic Testing

    May 1, 2020, 00:00
  • PBI19 BUDGET IMPACT ANALYSIS OF IXEKIZUMAB, GUSELKUMAB, RISANKIZUMAB AND/OR SECUKINUMAB FOR MANAGEMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE KINGDOM OF SAUDI ARABIA

    May 1, 2020, 00:00
  • PDG40 TRENDS IN UTILIZATION, REIMBURSEMENT, AND PRICE FOR ANTICOAGULANTS IN THE US MEDICAID POPULATION FROM 2000 TO 2018

    May 1, 2020, 00:00
  • PIH24 A CLINICAL AND ECONOMIC EVALUATION OF SURFACTANT THERAPY FOR MECONIUM ASPIRATION SYNDROME IN THE NEONATAL INTENSIVE CARE SETTING IN QATAR

    May 1, 2020, 00:00
  • PMS95 RHEUMATOID ARTHRITIS TREATMENT PROFILE IN THE BRAZILIAN PUBLIC HEALTH SYSTEM

    May 1, 2020, 00:00
  • PMD53 COMPARISON OF WOUND CLOSURE IN SURGICAL WOUNDS BETWEEN SINGLE-USE NEGATIVE PRESSURE WOUND THERAPY AND TRADITIONAL NEGATIVE PRESSURE WOUND THERAPY: A REAL WORLD ANALYSIS

    May 1, 2020, 00:00
  • PMD5 COMPARATIVE EFFECTIVENESS ASSESSMENT OF TWO POWERED SURGICAL STAPLING PLATFORMS IN LAPAROSCOPIC SLEEVE GASTRECTOMY

    May 1, 2020, 00:00
  • Biologics/Biosimilars/Regenerative Medicine - Health Technology Assessment

    May 1, 2020, 00:00
  • PIN14 UPDATING THE CMS MAJOR DIAGNOSTIC CATEGORIES (MDC) TO ALIGN WITH A PATHOPHYSIOLOGICAL MODEL OF DISEASE: IMPLICATIONS FOR RESEARCH AND CLINICAL CARE RESOURCE ALLOCATION

    May 1, 2020, 00:00
  • PMH23 ECONOMIC BURDEN OF SCHIZOPHRENIA AMONG YOUNG ADULTS WITH MEDICAID COVERAGE

    May 1, 2020, 00:00
  • PCV76 IDENTIFYING KNOWLEDGE GAPS IN HEART FAILURE (HF) RESEARCH AMONG WOMEN USING UNSUPERVISED MACHINE LEARNING METHODS

    May 1, 2020, 00:00
  • Infectious Diseases - Medical Technologies

    May 1, 2020, 00:00
  • PIN56 VACCINE EXPOSURE DURING PREGNANCY AMONG PRIVATELY AND PUBLICLY INSURED WOMEN IN THE UNITED STATES

    May 1, 2020, 00:00
  • PMD30 HETEROGENEITY OF PATIENTS TREATED WITH MULTI-PLANAR SOFTWARE-ASSISTED EXTERNAL FIXATION SYSTEMS (SPATIAL FRAMES) - ANALYSES OF PATIENT VARIABILITY AND OPERATIVE COMPLICATIONS

    May 1, 2020, 00:00
  • PDB18 ASSESSMENT OF THE HEALTH CARE UTILIZATION AND ECONOMIC BURDEN ON DIABETES PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE US VETERANS HEALTH ADMINISTRATION POPULATION

    May 1, 2020, 00:00
  • PMD54 COMPARISON OF WOUND CLOSURE IN PRESSURE ULCERS BETWEEN SINGLE-USE NEGATIVE PRESSURE WOUND THERAPY AND TRADITIONAL NEGATIVE PRESSURE WOUND THERAPY: A REAL WORLD ANALYSIS

    May 1, 2020, 00:00
  • PDB53 TRENDS IN PRICES OF INSULIN MARKETED IN THE US (1984-2020)

    May 1, 2020, 00:00
  • PDB65 EPIDEMIOLOGICAL DISEASE BURDEN OF NON-INSULIN-DEPENDENT DIABETES WITH COMPLICATIONS BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00
  • Differences in Patient-Reported Outcomes That Are Most Frequently Detected in Randomized Controlled Trials in Patients With Solid Tumors: A Pooled Analysis of 229 Trials

    May 1, 2020, 00:00
  • Individual's Health - Methodological Statistical Research

    May 1, 2020, 00:00
  • PMU56 IMPACT OF FDA APPROVAL OF NEW AGENTS ON THERAPEUTIC OPTIONS FOR GENETIC VARIANTS IN PEDIATRIC TUMORS

    May 1, 2020, 00:00
  • PBI32 EVOLUTION OF THE COST OF MEDICINES ACQUIRED BY THE COSTA RICAN SOCIAL SECURITY SYSTEM (CCSS) ACCORDINGLY TO ITS ORIGIN: BIOLOGICAL OR CHEMICAL SYNTHESIS

    May 1, 2020, 00:00
  • PDB12 EFFICACY AND SAFETY OF ETELCALCETIDE IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING DIALYSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2020, 00:00
  • PB2 ADHERENCE TO INJECTABLE ANTIDIABETIC THERAPIES (IAT) AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CHINA: RESULTS FROM A CROSS-SECTIONAL SURVEY STUDY

    May 1, 2020, 00:00
  • PMH33 VARIATION IN TREATMENT PERSISTENCE BETWEEN ACUTE AND CHRONIC OPIOID USERS RECEIVING BUPRENORPHINE PRODUCTS FOR OPIOID USE DISORDER

    May 1, 2020, 00:00
  • Alternative Medicine Nutrition - Medical Technologies

    May 1, 2020, 00:00
  • PMU47 NOSOCOMIAL INFLUENZA HOSPITALIZATIONS AMONG END-STAGE RENAL DISEASE PATIENTS DURING THE 2013-2014 THROUGH 2015-2016 INFLUENZA SEASONS

    May 1, 2020, 00:00
  • PDG63 FACTORS ASSOCIATED WITH SLEEPING MEDICATION USE AMONG ADULTS IN THE UNITED STATES

    May 1, 2020, 00:00
  • PCN9 TARGETED LITERATURE REVIEW (TLR) OF THE REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG MCRPC PATIENTS IN THE US

    May 1, 2020, 00:00
  • Drugs Generics - Organizational Practices

    May 1, 2020, 00:00
  • Individual's Health - Health Technology Assessment

    May 1, 2020, 00:00
  • PMD28 PERIOPERATIVE OUTCOME COMPARISON FOLLOWING UNILATERAL AND SIMULTANEOUS BILATERAL TOTAL KNEE ARTHROPLASTY

    May 1, 2020, 00:00
  • PMS6 EFFECTIVENESS AND ACCEPTABILITY OF AMITRIPTYLINE AND FOOD AND DRUG ADMINISTRATION-APPROVED TREATMENTS FOR FIBROMYALGIA: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00
  • PIH42 RECURRENT VAGINITIS AND CANDIDIASIS: BURDEN AMONG COMMERCIALLY INSURED WOMEN WITH TYPE II DIABETES IN THE US

    May 1, 2020, 00:00
  • Biologics/Biosimilars/Regenerative Medicine - Patient-Centered Research

    May 1, 2020, 00:00
  • PDG7 COST-EFFECTIVENESS ANALYSIS OF SULODEXIDE VERSUS DIOSMIN IN THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCY IN CHINA

    May 1, 2020, 00:00
  • PMH13 ANALYZING TRENDS IN MEDICAL EXPENDITURES ASSOCIATED WITH ALZHEIMER'S DISEASE AMONG U.S. ADULTS WITH DIABETES: 2013-2017

    May 1, 2020, 00:00
  • PIH47 DEMENTIA SEVERITY AND OPIOID USE IN LONG-TERM CARE NURSING HOME RESIDENTS

    May 1, 2020, 00:00
  • CC2 COST-EFFECTIVENESS ANALYSIS OF NEWBORN SCREENING AND TREATMENT FOR SPINAL MUSCULAR ATROPHY

    May 1, 2020, 00:00
  • PIH44 EPIDEMIOLOGICAL DISEASE BURDEN OF FEMALE INFERTILITY BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00
  • PDB97 DISEASE STATE AWARENESS AND ITS IMPACT ON DISEASE MANAGEMENT IN PATIENTS WITH TYPE 2 DIABETES IN QUETTA, PAKISTAN.

    May 1, 2020, 00:00
  • PMS58 EPIDEMIOLOGICAL DISEASE BURDEN OF INJURIES TO THE ELBOW AND FOREARM BASED ON ROUTINELY COLLECTED HEALTH INSURANCE CLAIMS DATA

    May 1, 2020, 00:00
  • Gastrointestinal Disorders - Methodological Statistical Research

    May 1, 2020, 00:00
  • PIH27 DIAGNOSING NEWBORNS WITH SUSPECTED SEVERE MITOCHONDRIAL DISORDERS: A COST-EFFECTIVENESS STUDY COMPARING EARLY WHOLE EXOME SEQUENCING TO STANDARD OF CARE

    May 1, 2020, 00:00
  • PDB24 ANNUAL HEALTH INSURANCE TREATMENT COST OF NON-INSULIN-DEPENDENT DIABETES MELLITUS WITH NEUROLOGICAL COMPLICATIONS BASED ON ROUTINELY COLLECTED FINANCING DATA

    May 1, 2020, 00:00
  • Alternative Medicine Nutrition - Economic Evaluation

    May 1, 2020, 00:00
  • PMH56 FITTING ITEM RESPONSE THEORY MODEL TO DETERMINE THE PSYCHOMETRIC PROPERTIES OF KESSLER PSYCHOLOGICAL DISTRESS SCALE AMONG WOMEN WHO EXCHANGE SEX

    May 1, 2020, 00:00
  • PMU16 IN-HOSPITAL OUTCOMES ASSOCIATED WITH HEART FAILURE AMONG WOMEN WITH BREAST CANCER IN THE U.S.: AN ANALYSIS OF THE 2012-2016 NATIONAL INPATIENT SAMPLE

    May 1, 2020, 00:00
  • PMU8 EVALUATION OF THE IMPACT OF AN INPATIENT DISCHARGE CARE PLANNING INTERVENTION ON HOSPITAL 30-DAY READMISSIONS AND COSTS IN A MEDICARE POPULATION

    May 1, 2020, 00:00
  • PIN8 HEPATITIS B TREATMENT PATTERNS IN US CLINICAL CARE FOLLOWING TENOFOVIR ALAFENAMIDE (TAF) APPROVAL

    May 1, 2020, 00:00
  • Infectious Diseases - Methodological Statistical Research

    May 1, 2020, 00:00
  • PDB93 NAFLD SIMULATOR: A WEB-BASED SIMULATION TOOL TO PREDICT LONG-TERM OUTCOMES OF NON-ALCOHOLIC FATTY LIVER DISEASE

    May 1, 2020, 00:00
  • Musculoskeletal Disorders - Real World Data Information Systems

    May 1, 2020, 00:00
  • PDG15 ECONOMIC ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST USING REAL-WORLD DATA

    May 1, 2020, 00:00
  • Injury Regulatory

    May 1, 2020, 00:00
  • PCV68 PREDICTORS OF FAILURE-TO-RESCUE FOR ACUTE MYOCARDIAL INFARCTION

    May 1, 2020, 00:00
  • PMH46 GEOGRAPHIC VARIATION IN TREATMENT ADMISSIONS FOR OPIOID USE DISORDER IN CINCINNATI COMPARED TO THE UNITED STATES

    May 1, 2020, 00:00
  • PMS25 CLINICAL VALIDATION OF A BUDGET IMPACT MODEL USING THE ESTABLISHED KEY OPINION LEADER VALIDATION FRAMEWORK (KOLVF)

    May 1, 2020, 00:00
  • PDG48 PRESCRIBING PRACTICES FOR HYPERLIPIDEMIA AMONG U.S. AMBULATORY PATIENTS

    May 1, 2020, 00:00
  • PMH35 MENTAL AND BEHAVIORAL DISORDERS DUE TO OPIOID USE IN COLOMBIA: PREVALENCE AND DEMOGRAPHIC CHARACTERISTICS 2009-2018

    May 1, 2020, 00:00
  • Medical Devices - Health Policy Regulatory

    May 1, 2020, 00:00
  • PIH10 COST-EFFECTIVENESS ANALYSIS OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN OSTEOARTHRITIS IN CHINA

    May 1, 2020, 00:00
  • PAM11 DEVELOPMENT AND EVALUATION OF THE BLOOD DEFICIENCY QUESTIONNAIRE (BDQ)

    May 1, 2020, 00:00
  • PIH4 NUMBER NEEDED TO TREAT (NNT) WITH FENFLURAMINE TO ACHIEVE A CLINICALLY MEANINGFUL REDUCTION IN CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME: HEALTH ECONOMIC IMPLICATIONS

    May 1, 2020, 00:00
  • PMU11 ASSOCIATION BETWEEN DEPRESSION AND HEALTHCARE EXPENDITURES AMONG STROKE SURVIVORS

    May 1, 2020, 00:00
  • PDG56 APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN CHINA NATIONAL REIMBURSEMENT DRUG LIST PRICE NEGOTIATIONS: THE EVOLVING TREND AND IMPLICATIONS

    May 1, 2020, 00:00
  • PDB4 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF THE EFFECT OF NALTREXONE/ BUPROPION COMPARED WITH OTHER ANTI-OBESITY DRUGS IN OVERWEIGHT AND OBESE PATIENTS

    May 1, 2020, 00:00
  • PIH20 OUTCOME AND ECONOMIC EVALUATION OF NEONATAL SCREENING USING MS/MS FOR INHERITED METABOLIC DISEASES

    May 1, 2020, 00:00
  • PDB32 COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VS. CANAGLIFLOZIN 300 MG IN PATIENTS WITH TYPE 2 DIABETES IN A CANADIAN SETTING

    May 1, 2020, 00:00
  • PCV56 COMPARISON OF THE FRAMINGHAM, PROCAM AND MODIFIED FRAMINGHAM RISK SCORES FOR PREDICTING CARDIOVASCULAR EVENTS IN A COHORT FROM A CARDIOVASCULAR PREVENTION PROGRAM IN THE CARIBBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00
  • PIN7 REAL-WORLD EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS (DAA) IN YOUNG ADULT (18-25) AND ELDERLY (80+) POPULATIONS WITH HEPATITIS C (HCV)

    May 1, 2020, 00:00
  • PDG3 EVALUATION OF PROGESTERONE (17-ALPHA HYDROXYPROGESTERONE CAPROATE (17-OHPC)) UTILIZATION, ADHERENCE, AND OUTCOMES IN WOMEN WITH A HIGH-RISK PREGNANCY

    May 1, 2020, 00:00
  • PMD32 RISK AND OUTCOMES FOLLOWING APPLICATION OF MULTI-PLANAR RING FIXATION SYSTEMS - A TWELVE YEAR REVIEW FROM A US CLAIMS DATABASE ANALYSIS

    May 1, 2020, 00:00
  • PIN57 UPTAKE OF PRE-EXPOSURE PROPHYLAXIS (PREP) AND TYPE OF PROVIDERS AMONG COMMERCIALLY-INSURED PERSONS IN THE UNITED STATES, 2012-2018

    May 1, 2020, 00:00
  • Addressing Challenges of Economic Evaluation in Precision Medicine Using Dynamic Simulation Modeling

    May 1, 2020, 00:00
  • PDB42 BUDGET IMPACT ANALYSIS OF SENSOR-AUGMENTED PUMP IN TYPE 1 DIABETES MELLITUS COMPARED WITH CONTINUOUS SUBCUTANEOUS INSULIN INFUSION IN THE RUSSIAN FEDERATION

    May 1, 2020, 00:00
  • PGI36 ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EUROQOL-5 DIMENSIONS (EQ-5D) FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION

    May 1, 2020, 00:00
  • PIN36 BUDGETARY IMPACT ANALYSIS OF PREEXPOSURE PROPHYLAXIS (PREP) STRATEGY FOR THE PREVENTION OF HIV IN COLOMBIA, 2019-2021

    May 1, 2020, 00:00
  • PMH60 SURVEY OF PATIENT EXPERIENCE AND BURDEN OF ILLNESS IN WOMEN WITH POSTPARTUM DEPRESSION

    May 1, 2020, 00:00
  • PDG29 DROSPIRENONE INDUCED GALL BLADDER DISEASES: A RETROSPECTIVE STUDY OF EUDRAVIGILANCE DATABASE

    May 1, 2020, 00:00
  • PIH31 INVERSE RELATIONSHIP BETWEEN ANEMIA IN THE THIRD TRIMESTER OF PREGNANCY AND LOW BIRTH WEIGHT IN A REFERENCE MATERNITY UNIT OF A CARRIBEAN REGION OF COLOMBIA

    May 1, 2020, 00:00
  • PDG10 COST-EFFECTIVENESS OF CELECOXIB VERSUS IBUPROFEN AND NAPROXEN IN PATIENTS WITH OSTEOARTHRITIS IN UNITED ARAB EMIRATES AND SAUDI ARABIA BASED ON RESULTS FROM THE PRECISION TRIAL

    May 1, 2020, 00:00
  • PBI31 MANAGED ENTRY AGREEMENTS FOR ATMPS DESPITE ACCESS ALREADY GRANTED? THE CASE OF GERMANY

    May 1, 2020, 00:00
  • Multiple Diseases - Health Policy Regulatory

    May 1, 2020, 00:00
  • PMS40 REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF ROTATOR CUFF TEAR PATIENTS IN THE US

    May 1, 2020, 00:00
  • PIN35 UTILIZATION, SPENDING AND PRICE TRENDS FOR ANTIVIRAL (FLU AGENTS) IN THE US MEDICAID PROGRAMS: EMPIRICAL DATA ANALYSIS FROM 1999-2018.

    May 1, 2020, 00:00
  • PDB95 FACTORS ASSOCIATED WITH MEDICATION NON-ADHERENCE AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES

    May 1, 2020, 00:00
  • Infectious Diseases - Epidemiology Public Health

    May 1, 2020, 00:00
  • PMU39 COOKING AT HOME CAN SAVE MONEY, REGARDLESS OF FOOD PRICE: A MULTILEVEL ANALYSIS OF MEALS PREPARED AWAY FROM THE HOME ON DIET MEASURES AND FOOD EXPENDITURES

    May 1, 2020, 00:00
  • PIH36 TIME TO CONFIRMATORY TESTING OF CHILDREN AGE 72 MONTHS FOR ELEVATED BLOOD LEAD

    May 1, 2020, 00:00
  • PDG47 OUTPATIENT OPIOID PRESCRIBING AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: ANALYSIS OF NATIONAL AMBULATORY MEDICAL CARE SURVEY, 2011-2016

    May 1, 2020, 00:00
  • PIN90 COMPARATIVE QUALITY OF LIFE OUTCOMES OF DOLUTEGRAVIR-BASED OR EFAVIRENZ-BASED ANTIRETOVIRAL TREATMENT IN PREGNANCY FOR LATE PRESENTORS BETWEEN THE 3RD TRIAL-MESTER AND 48 WEEKS POSTPARTUM

    May 1, 2020, 00:00
  • PIH35 LONG-TERM PRESCRIPTION OPIOID USE AMONG OLDER ADULTS IN THE UNITED STATES

    May 1, 2020, 00:00
  • PMU7 IS THE TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION FIT-FOR-PURPOSE?: A MIXED-METHODS APPROACH

    May 1, 2020, 00:00
  • PMS52 EPIDEMIOLOGY OF DERMATITIS ATOPIC IN AMERICA: SYSTEMATIC REVIEW

    May 1, 2020, 00:00
  • PMU45 FACTORS ASSOCIATED WITH NEGATIVE SELF RATED HEALTH (SRH) IN A PRIVATE HEALTH PLAN IN BRAZIL

    May 1, 2020, 00:00
  • PCN15 EFFICACY, EFFECTIVENESS, AND SAFETY OF FRONTLINE TREATMENTS FOR PERIPHERAL T-CELL LYMPHOMA

    May 1, 2020, 00:00
  • PDG57 EFFICACY AND SAFETY OF FLAVONOIDS IN ADULT PATIENTS WITH HEMORRHOIDS: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00
  • PGI23 TREATMENT COST ANALYSIS FOR PATIENTS IN THE UNITED STATES WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE AN INADEQUATE RESPONSE OR WHO ARE INTOLERANT TO TNF BLOCKERS

    May 1, 2020, 00:00
  • PDB69 FACTORS ASSOCIATED WITH PRE-DIABETES IN THE U.S ‘DIABETES-BELT’ REGION POPULATION

    May 1, 2020, 00:00
  • Individual's Health - Real World Data Information Systems

    May 1, 2020, 00:00
  • PMD45 COMPARISON OF WOUND CLOSURE IN CHRONIC LOWER EXTREMITY ULCERS BETWEEN SINGLE-USE NEGATIVE PRESSURE WOUND THERAPY AND TRADITIONAL NEGATIVE PRESSURE WOUND THERAPY: A REAL WORLD ANALYSIS

    May 1, 2020, 00:00
  • PMU65 EVALUATION OF HOME HEALTH FOR PATIENTS ELIGIBLE FOR THE POST-ACUTE CARE TRANSFER POLICY

    May 1, 2020, 00:00
  • PMH8 EFFECT OF DEPRESSION ON WORK PRODUCTIVITY COSTS AND EMPLOYMENT

    May 1, 2020, 00:00
  • Mental Health - Methodological Statistical Research

    May 1, 2020, 00:00
  • PDG20 HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS

    May 1, 2020, 00:00
  • PIN19 A COST EFFECTIVENESS ANALYSIS OF ACTIVE CASE FINDING AND PASSIVE CASE FINDING FOR CASE DETECTION OF TUBERCULOSIS AT KISUGU HC III,KAMPALA UGANDA.

    May 1, 2020, 00:00
  • PMU20 A DEVICE CATEGORY-BASED ECONOMIC MODEL EXPLORING ELECTROSURGERY TECHNOLOGIES ACROSS PROCEDURE TYPES: A UNITED STATES ANALYSIS

    May 1, 2020, 00:00
  • PMS7 THE ROLE OF SPECIALIZED PRO-RESOLVING LIPID MEDIATORS IN THE TREATMENT OF INFLAMMATION CAUSED BY EXERCISING: A SYSTEMATIC REVIEW

    May 1, 2020, 00:00
  • PIH63 THE EFFICACY OF TREATMENTS FOR ATOPIC DERMATITIS IN CHILDREN: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00
  • PIN20 SOCIETAL PRODUCTIVITY GAINS FROM NEW THERAPIES IN HEPATITIS C

    May 1, 2020, 00:00
  • PGI21 COST PER ACCEPTABLE LIFE-YEARS AND COST PER QALY GAINS IN NON-ACCEPTABLE HEALTH STATE FOR BIOLOGICAL TREATMENT IN CROHN'S DISEASE, A NOVEL APPROACH IN HEALTH ECONOMIC MODELLING

    May 1, 2020, 00:00
  • PDB68 CHARACTERISTICS OF PATIENTS WITH SEVERE HYPOGLYCEMIA AMONG PATIENTS WITH DIABETES USING INSULIN IN COMMERCIALLY INSURED, MEDICARE, AND MEDICAID POPULATION

    May 1, 2020, 00:00
  • Advanced Analytics Studies

    May 1, 2020, 00:00
  • PIH21 EFFICACY AND SAFETY OF IMRECOXIB, CELECOXIB AND DICLOFENAC IN PATIENTS WITH OSTEOARTHRITIS: A NETWORK META-ANALYSIS

    May 1, 2020, 00:00
  • PIH58 GEOGRAPHICAL DISPARITIES IN NON-UTILIZATION OF HEALTH FACILITY DELIVERY AND POSTNATAL SERVICES IN GHANA

    May 1, 2020, 00:00
  • PMH12 TRAJECTORY IN HYPNOTIC DRUG USE, SELF-PERCEIVED HEALTH, AND HEALTHCARE EXPENDITURES AMONG PATIENTS DIAGNOSED WITH ANXIETY DISORDERS

    May 1, 2020, 00:00
  • PDG14 BUDGET IMPACT ANALYSIS OF GIPAP AND VPAP TERMINATION WITHIN THE NEXT 5 YEARS IN VIETNAM

    May 1, 2020, 00:00
  • PDG41 CLOSURE OF THE PART D COVERAGE GAP AND OUT-OF-POCKET COSTS FOR RHEUMATOID ARTHRITIS BIOLOGICS IN MEDICARE PART D

    May 1, 2020, 00:00
  • Editorial Board

    Apr 21, 2020, 08:38
  • Public Attitudes on Lung Cancer Screening and Radiation Risk: A Best-Worst Experiment

    Apr 1, 2020, 00:00
  • Is There a Future for Value-Based Contracting? [Editor's Choice]

    Apr 1, 2020, 00:00
  • A Systematic Review of the Feasibility and Psychometric Properties of the ICEpop CAPability Measure for Adults and Its Use So Far in Economic Evaluation

    Apr 1, 2020, 00:00
  • Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France

    Apr 1, 2020, 00:00
  • Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report [Editor's Choice]

    Apr 1, 2020, 00:00
  • Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications

    Apr 1, 2020, 00:00
  • Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts

    Apr 1, 2020, 00:00
  • Are Value-Based Arrangements the Answer We’ve Been Waiting for?

    Apr 1, 2020, 00:00
  • Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match? [Editor's Choice]

    Apr 1, 2020, 00:00
  • Table of Contents

    Apr 1, 2020, 00:00
  • Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users

    Apr 1, 2020, 00:00
  • Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim

    Apr 1, 2020, 00:00
  • Reporting Quality of Discrete Event Simulations in Healthcare—Results From a Generic Reporting Checklist

    Apr 1, 2020, 00:00
  • Copyright/Subscription

    Apr 1, 2020, 00:00
  • Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma

    Apr 1, 2020, 00:00
  • Pharmaceutical Products and Their Value: Lessons Learned and the Path Ahead

    Apr 1, 2020, 00:00
  • Managed Entry Agreements: Policy Analysis From the European Perspective [Editor's Choice]

    Apr 1, 2020, 00:00
  • Editorial Board

    Mar 18, 2020, 10:02
  • Author's Reply

    Mar 1, 2020, 00:00
  • Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis

    Mar 1, 2020, 00:00
  • Socioeconomic Status of Newborns and Hospital Efficiency: Implications for Hospital Payment Methods

    Mar 1, 2020, 00:00
  • How Are Debriefing Questions Used in Health Discrete Choice Experiments? An Online Survey

    Mar 1, 2020, 00:00
  • Mapping WOMAC Onto the EQ-5D-5L Utility Index in Patients With Hip or Knee Osteoarthritis

    Mar 1, 2020, 00:00
  • Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?

    Mar 1, 2020, 00:00
  • Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting [Editor's Choice]

    Mar 1, 2020, 00:00
  • Moving Beyond the Tip of the Iceberg to Incorporate Patients’ Perspectives and Outcomes in the Medical Device Regulatory Process

    Mar 1, 2020, 00:00
  • Cost-Effectiveness Analysis of Screening for Persistent Hepatitis E Virus Infection in Solid Organ Transplant Patients in the United Kingdom: A Model-Based Economic Evaluation

    Mar 1, 2020, 00:00
  • Table of Contents

    Mar 1, 2020, 00:00
  • Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs [Editor's Choice]

    Mar 1, 2020, 00:00
  • Measuring Quality-Adjusted Life-Years When Health Fluctuates

    Mar 1, 2020, 00:00
  • A Step Closer to Better Research Prioritization? The ISPOR Value of Information Task Force Reports

    Mar 1, 2020, 00:00
  • Psychometric Analysis of the Abdominal Score From the Diary for Irritable Bowel Syndrome Symptoms–Constipation Using Phase IIb Clinical Trial Data

    Mar 1, 2020, 00:00
  • Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force [Editor's Choice]

    Mar 1, 2020, 00:00
  • Subscription Page

    Mar 1, 2020, 00:00
  • Letter to the Editor: Methods for Measuring Multiple Medication Adherence: A Systematic Review

    Mar 1, 2020, 00:00
  • Integrating the Voice of the Patient Into the Medical Device Regulatory Process Using Patient Preference Information

    Mar 1, 2020, 00:00
  • Computing PROPr Utility Scores for PROMIS® Profile Instruments

    Mar 1, 2020, 00:00
  • Economic Evaluation of User-Fee Exemption Policies for Maternal Healthcare in Burkina Faso: Evidence From a Cost-Effectiveness Analysis

    Mar 1, 2020, 00:00
  • Exploratory Factor Analysis of a Patient-Centered Cancer Care Measure to Support Improved Assessment of Patients’ Experiences

    Mar 1, 2020, 00:00
  • Editorial Board

    Feb 27, 2020, 10:34
  • Health-Related Quality of Life in Children With Low Language or Congenital Hearing Loss, as Measured by the PedsQL and Health Utility Index Mark 3

    Feb 1, 2020, 00:00
  • “Stick or Twist?” Negotiating Price and Data in an Era of Conditional Approval

    Feb 1, 2020, 00:00
  • Copyright/Subscription

    Feb 1, 2020, 00:00
  • Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development [Editor's Choice]

    Feb 1, 2020, 00:00
  • Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus

    Feb 1, 2020, 00:00
  • Clinical Effectiveness of Decision Support for Prescribing Opioids for Chronic Noncancer Pain: A Prospective Cohort Study

    Feb 1, 2020, 00:00
  • Table of Contents

    Feb 1, 2020, 00:00
  • Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana

    Feb 1, 2020, 00:00
  • Comparison of Different Case-Crossover Variants in Handling Exposure-Time Trend or Persistent-User Bias: Using Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure as an Example

    Feb 1, 2020, 00:00
  • To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland

    Feb 1, 2020, 00:00
  • Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation

    Feb 1, 2020, 00:00
  • Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems [Editor's Choice]

    Feb 1, 2020, 00:00
  • Optimal Design of Population-Level Financial Incentives of Influenza Vaccination for the Elderly

    Feb 1, 2020, 00:00
  • A Head-On Ordinal Comparison of the Composite Time Trade-Off and the Better-Than-Dead Method

    Feb 1, 2020, 00:00
  • What Difference Does It Make? A Comparison of Health State Preferences Elicited From the General Population and From People With Multiple Sclerosis

    Feb 1, 2020, 00:00
  • Value-Based Pharmaceutical Contracts: Value for Whom?

    Feb 1, 2020, 00:00
  • Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions [Editor's Choice]

    Feb 1, 2020, 00:00
  • Effects of Lean Healthcare on Patient Flow: A Systematic Review

    Feb 1, 2020, 00:00
  • Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force

    Feb 1, 2020, 00:00
  • Author's Reply

    Feb 1, 2020, 00:00
  • Editorial Board

    Jan 15, 2020, 08:20
  • Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary

    Jan 1, 2020, 00:00
  • Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review

    Jan 1, 2020, 00:00
  • Copyright/Subscription

    Jan 1, 2020, 00:00
  • Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations

    Jan 1, 2020, 00:00
  • Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review

    Jan 1, 2020, 00:00
  • Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System

    Jan 1, 2020, 00:00
  • Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis [Editor's Choice]

    Jan 1, 2020, 00:00
  • Costs and Benefits of Alternative Strategies to Control the Spread of Livestock-Acquired Methicillin-Resistant Staphylococcus Aureus From Pig Production

    Jan 1, 2020, 00:00
  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

    Jan 1, 2020, 00:00
  • A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C

    Jan 1, 2020, 00:00
  • HTA Around the World: Broadening Our Understanding of Cross-Country Differences [Editor's Choice]

    Jan 1, 2020, 00:00
  • Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis [Editor's Choice]

    Jan 1, 2020, 00:00
  • Concepts and Instruments for Patient-Reported Outcome Assessment in Celiac Disease: Literature Review and Experts’ Perspectives

    Jan 1, 2020, 00:00
  • Table of Contents

    Jan 1, 2020, 00:00
  • Development of System Performance Indicators for Adolescent and Young Adult Cancer Care and Control in Canada

    Jan 1, 2020, 00:00
  • Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands

    Jan 1, 2020, 00:00
  • Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?

    Jan 1, 2020, 00:00
  • The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review

    Jan 1, 2020, 00:00
  • Disclosure Information

    Dec 17, 2019, 09:25
  • Editorial Board

    Dec 3, 2019, 08:15
  • Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study

    Dec 1, 2019, 00:00
  • Table of Contents

    Dec 1, 2019, 00:00
  • Excess Costs and Economic Burden of Obesity-Related Cancers in the United States [Editor's Choice]

    Dec 1, 2019, 00:00
  • Measuring Productivity Costs in Patients With Musculoskeletal Disorders: Measurement Properties of the Institute for Medical Technology Assessment Productivity Cost Questionnaire

    Dec 1, 2019, 00:00
  • Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

    Dec 1, 2019, 00:00
  • How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L [Editor's Choice]

    Dec 1, 2019, 00:00
  • Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model

    Dec 1, 2019, 00:00
  • Propensity Score Weighting Using Overlap Weights: A New Method Applied to Regorafenib Clinical Data and a Cost-Effectiveness Analysis

    Dec 1, 2019, 00:00
  • Community-Based Services by Pharmacists: A Systematic Review of Cost-Utility Analyses

    Dec 1, 2019, 00:00
  • Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial

    Dec 1, 2019, 00:00
  • Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?

    Dec 1, 2019, 00:00
  • Copyright/Subscription

    Dec 1, 2019, 00:00
  • Does the Institute for Clinical and Economic Review Revise Its Findings in Response to Industry Comments? [Editor's Choice]

    Dec 1, 2019, 00:00
  • Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017

    Dec 1, 2019, 00:00
  • Carer Social Care-Related Quality of Life Outcomes: Estimating English Preference Weights for the Adult Social Care Outcomes Toolkit for Carers

    Dec 1, 2019, 00:00
  • Cost-Effectiveness of Antihypertensive Therapy in Patients Older Than 80 Years: Cohort Study and Markov Model

    Dec 1, 2019, 00:00
  • Editorial Board

    Nov 13, 2019, 17:52
  • CC2 ECONOMIC ASSESSMENT OF A HIGH DOSE VERSUS A STANDARD DOSE INFLUENZA VACCINE IN THE US VETERAN POPULATION: ESTIMATING THE IMPACT ON HOSPITALIZATION COST FOR CARDIOVASCULAR AND RESPIRATORY DISEASE

    Nov 1, 2019, 00:00
  • PNS273 ICER: SIMILARITIES AND DIFFERENCES BETWEEN UK (ENGLAND) AND USA COST-EFFECTIVENESS WATCHDOGS

    Nov 1, 2019, 00:00
  • PMU29 ECONOMIC EVALUATION FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURES INFECTIONS (ABSSSI) FROM THE NATIONAL PAYER PERSPECTIVE: INTRODUCTION OF A NEW TREATMENT INTO THE PATIENT JOURNEY. SIMULATION IN 3 EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00
  • PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2019, 00:00
  • PCN193 COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN COMBINATION WITH PLATINUM CHEMOTHERAPY AND PEMETREXED FOR PREVIOUSLY UNTREATED PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN ENGLAND

    Nov 1, 2019, 00:00
  • PMS52 CLINICAL GUIDELINE DEVELOPMENT FOR THE MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN IN PRIMARY CARE

    Nov 1, 2019, 00:00
  • PCN103 A COMPARISON OF PARTITIONED-SURVIVAL AND STATE TRANSITION MODELLING APPROACHES - FINDINGS FROM A CASE STUDY IN ONCOLOGY

    Nov 1, 2019, 00:00
  • PDB123 CURRENT STATUS AND USE OF RESOURCES OF LYSOSOMAL STORAGE DISEASES: ANALYSIS OF A SPANISH CLAIMS DATABASE

    Nov 1, 2019, 00:00
  • PDB72 DEPRIVATION - MAIN CAUSE OF DIABETIC FOOT ULCER IN GERMANY

    Nov 1, 2019, 00:00
  • PCN141 USE OF COST-EFFECTIVENESS AFFORDABILITY CURVES IN EVALUATING CANCER DRUGS IN ENGLAND

    Nov 1, 2019, 00:00
  • PDB52 ECONOMIC BURDEN ASSOCIATED WITH DIABETIC RETINOPATHY: EVIDENCE FROM A LITERATURE REVIEW

    Nov 1, 2019, 00:00
  • PCN68 BRENTUXIMAB VEDOTIN FOR CONSOLIDATION THERAPY AFTER ASCT IN CD30+ HODGKIN'S LYMPHOMA: A SUSTAINABLE PHARMACEUTICAL EXPENDITURE FOR THE ITALIAN NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00
  • Alternative Medicine Nutrition - Clinical Outcomes

    Nov 1, 2019, 00:00
  • PRO132 DISEASE BURDEN OF X-LINKED HYPOPHOSPHATEMIA

    Nov 1, 2019, 00:00
  • Alternative Medicine Nutrition - Economic Evaluation

    Nov 1, 2019, 00:00
  • PNS182 SYSTEMIC ADMINISTRATION OF GLUCOCORTICOIDS IN GUIZHOU PROVINCE, CHINA: A SURVEY AMONG HOSPITAL PHARMACIES.

    Nov 1, 2019, 00:00
  • PNS350 ANALYSIS OF HEALTH CARE WORKERS' MIGRATION: THE MOTIVATIONS OF HUNGARIAN PHISIOTHERAPISTS FOR WORKING ABROAD

    Nov 1, 2019, 00:00
  • PNS291 ANALYSIS OF RECALLS OF MEDICAL DEVICES FROM 2009 TO 2018 BY RISK CLASS AND DEVICE CATEGORY BASED ON ITALIAN DATA

    Nov 1, 2019, 00:00
  • PIN115 ANALYZING SOCIO-ECONOMIC INEQUALITY IN CHILDHOOD IMMUNIZATION COVERAGE IN ETHIOPIA

    Nov 1, 2019, 00:00
  • PIH56 PLACE OF COMPLEMENTARY MEDICINES AND OPPORTUNITIES IN THE MANAGEMENT OF GYNECOLOGICAL CANCER PATIENTS

    Nov 1, 2019, 00:00
  • PUK9 MEDICO-ECONOMIC EVALUATION OF HAEMODIAFILTRATION IN COMPARISON TO HIGH FLUX DIALYSIS

    Nov 1, 2019, 00:00
  • PCV104 A SYSTEMATIC REVIEW OF ORGANISATIONAL AND SERVICE SPECIFICATION RECOMMENDATIONS FOR CENTRES PROVIDING PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2019, 00:00
  • PBI24 SECUKINUMAB VS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ALGERIAN PERSPECTIVE

    Nov 1, 2019, 00:00
  • PMU4 WHAT IS A GOOD OR BAD NUMBER NEED TO TREAT (NNT) VALUE? A LITERATURE REVIEW

    Nov 1, 2019, 00:00
  • PNS311 PREDICTIVE-ADJUSTED INDIRECT COMPARISON (PAIC): A NOVEL METHOD FOR POPULATION-ADJUSTED INDIRECT COMPARISON

    Nov 1, 2019, 00:00
  • PCV6 BURDEN OF MORTALITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION - A LITERATURE REVIEW

    Nov 1, 2019, 00:00
  • PCV141 ATHEROSCLEROSIS: REAL-WORLD INSIGHTS FROM A PORTUGUESE PRIMARY CARE DATABASE

    Nov 1, 2019, 00:00
  • PIH61 VALIDATION OF THE STUDY MEDICATION SATISFACTION QUESTIONNAIRE (SMSQ). A MEASURE OF MEDICATION SATISFACTION DESIGNED FOR INDIVIDUALS TAKING PRE-EXPOSURE PROPHYLAXIS (PREP) MEDICATION FOR HIV

    Nov 1, 2019, 00:00
  • PMU100 A SYSTEMATIC REVIEW OF PREVIOUSLY PUBLISHED OR APPRAISED HEALTH ECONOMIC ESTIMATING THE SHORT- AND LONG-TERM CONSEQUENCES OF STEROID-SPARING AGENTS

    Nov 1, 2019, 00:00
  • PDG74 AN ANALYSIS OF RESTRICTED RECOMMENDATIONS BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Nov 1, 2019, 00:00
  • PMU50 UNFOLD THE MYSTERY OF PRICE NEGOTIATION IN CHINA: HOW REIMBURSEMENT PAYMENT STANDARD WAS FORMULATED

    Nov 1, 2019, 00:00
  • PIN130 COST-EFFECTIVENESS ANALYSIS OF CEFTAZIDIME/AVIBACTAM FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS IN BULGARIA

    Nov 1, 2019, 00:00
  • PNS140 POTENTIAL IMPACTS OF THE U.K. VOLUNTARY SCHEME FOR BRANDED MEDICINES PRICING AND ACCESS: A REVIEW OF STAKEHOLDER OPINION

    Nov 1, 2019, 00:00
  • PIH40 ASSESSING HEALTH DISPARITY IN THE ELDERLY POPULATION WITH DIFFERENT ECONOMIC STATUS IN SOUTH KOREA: FOCUSING ON HIP FRACTURE

    Nov 1, 2019, 00:00
  • PSU34 COMPLICATIONS AND REIMBURSEMENT AMONG PATIENTS WITH HAMMERTOE SURGERY: A MEDICARE SUPPLEMENTAL DATABASE STUDY WITH TWO YEARS FOLLOW-UP

    Nov 1, 2019, 00:00
  • PUK12 ANALYSIS OF COST AND CONSEQUENCES RELATED TO THE PERSISTENCE OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS AND THEIR IMPACT ON QUALITY OF LIFE IN PATIENTS AGED ≥ 65 YEARS WITH OVERACTIVE BLADDER IN SPAIN

    Nov 1, 2019, 00:00
  • PMU43 A MORE ACCURATE MEASURE OF AFFORDABILITY OF ALCOHOL FOR THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00
  • PCN178 MODELLING THE BUDGET IMPACT OF INTRODUCING 3D MAMMOGRAPHY FOR BREAST CANCER SCREENING IN GERMANY

    Nov 1, 2019, 00:00
  • PNS53 REVIEW OF METHODOLOGICAL QUALITY OF BUDGET IMPACT ANALYSES FOR ORPHAN DRUGS

    Nov 1, 2019, 00:00
  • PNS347 SCIENTIFIC OUTCOME OF ISPOR CONFERENCES: AN ANALYSIS OF 44,390 ABSTRACTS PRESENTED AT 38 ISPOR CONFERENCES BETWEEN 2002-2018

    Nov 1, 2019, 00:00
  • Alternative Medicine Nutrition - Patient-Centered Research

    Nov 1, 2019, 00:00
  • PDB57 COST SAVINGS ASSOCIATED WITH PREMIX VERSUS BASAL-BOLUS REGIMEN IN ALGERIAN PATIENTS WITH TYPE 2 DIABETES INSUFFICIENTLY CONTROLLED UNDER BASAL INSULIN REGIMEN

    Nov 1, 2019, 00:00
  • PNS109 PERCEPTIONS AND PRACTICES OF SELF- MEDICATION IN AN INDIAN URBAN COMMUNITY

    Nov 1, 2019, 00:00
  • PGI10 COST-UTILITY ANALYSIS OF USTEKINUMAB VS VEDOLIZUMAB IN CROHN DISEASE IN ITALY

    Nov 1, 2019, 00:00
  • PNS91 ACCESS AND UTILIZATION OF MATERNAL HEALTHCARE IN A RURAL DISTRICT IN THE FOREST BELT OF GHANA

    Nov 1, 2019, 00:00
  • Musculoskeletal Disorders - Health Policy Regulatory

    Nov 1, 2019, 00:00
  • PRO10 QUALITATIVE STUDY TO ESTABLISH THE CONTENT VALIDITY OF THE ABC-CFXS FOR EVALUATION OF TREATMENT EFFICACY IN FRAGILE X SYNDROME

    Nov 1, 2019, 00:00
  • PCN15 PROPHYLAXIS FOR BICALUTAMIDE-INDUCED GYNECOMASTIA: A NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00
  • PMD19 ECONOMIC EVALUATION OF CATARACT PHACOEMULSIFICATION IN THE RUSSIAN FEDERATION

    Nov 1, 2019, 00:00
  • PR3 HOME-BASED ASSESSMENT OF PATIENT REPORTED OUTCOME MEASURES USING A SMARTPHONE APP PLATFORM: A FEASIBILITY STUDY

    Nov 1, 2019, 00:00
  • PMU68 THE ROLE OF OUTCOMES-BASED MODELS FOR THE REIMBURSEMENT OF MEDICINES IN THE UK NATIONAL HEALTH SERVICE

    Nov 1, 2019, 00:00
  • PNS20 RECENT ADVANCES IN THE EUROPEAN CROSS-BORDER COLLABORATIONS IN JOINT DRUG PROCUREMENT LANDSCAPE

    Nov 1, 2019, 00:00
  • PRO115 DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

    Nov 1, 2019, 00:00
  • PCN293 POST-PROGRESSION ENDPOINTS IN ONCOLOGY TRIALS: CURRENT CLINICAL AND REIMBURSEMENT PERSPECTIVES

    Nov 1, 2019, 00:00
  • PIN44 COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINATION IN THE DUTCH NATIONAL INFLUENZA PREVENTION PROGRAM

    Nov 1, 2019, 00:00
  • PMS78 CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00
  • PRS21 PRODUCTIVITY LOSSES FOR ALLERGIC RHINITIS PATIENTS IN THE NETHERLANDS AND SWEDEN

    Nov 1, 2019, 00:00
  • PCV73 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS WARFARIN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION IN THE JAPANESE HEALTHCARE SETTING

    Nov 1, 2019, 00:00
  • PDB76 IMPACT OF COPAYMENT INCREASE OF ANTIDIABETIC MEDICATIONS ON GLYCAEMIC CONTROL IN FINNISH PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2019, 00:00
  • PDB15 THE COST OF HYPOGLYCAEMIA IN TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS

    Nov 1, 2019, 00:00
  • PNS57 BUDGET IMPACT ANALYSIS OF A WEARABLE REMOTE CONTINUOUS MONITORING DEVICE TO FACILITATE EARLY DISCHARGE OF BARIATRIC SURGERY PATIENTS IMMEDIATELY AFTER POSTOPERATIVE OBSERVATION IN THE RECOVERY WARD

    Nov 1, 2019, 00:00
  • PRO135 PROJECT HERCULES: A SYSTEMATIC REVIEW OF THE CONTENT AND STRUCTURAL VALIDITY OF PROS USED TO ASSESS QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY (DMD)

    Nov 1, 2019, 00:00
  • PCV46 BUDGET IMPACT OF A DUAL-LAYER STENT RETRIEVER (DLSR) IN THE TREATMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS) FROM HOSPITAL'S PERSPECTIVE IN FRANCE AND SWEDEN

    Nov 1, 2019, 00:00
  • PCV50 COST-EFFECTIVENESS OF TARGETED SCREENING USING A MACHINE LEARNING RISK PREDICTION TOOL FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION

    Nov 1, 2019, 00:00
  • PMU66 TIMEFRAME FOR DRUG MARKETING AUTHORIZATION IN EUROPE

    Nov 1, 2019, 00:00
  • PIN71 PURSUING ELIMINATION OF HEPATITIS C IN EGYPT: AN ECONOMIC EVALUATION OF A COUNTRY-WIDE PROGRAM AND ITS ASSOCIATED COST EFFECTIVENESS

    Nov 1, 2019, 00:00
  • PNS38 PROPOSING AND EVALUATING A DESIGN FOR GDPR-COMPLIANT, SCALABLE TECHNOLOGY FOR AUTOMATIC ADJUDICATION OF RISK-SHARING AGREEMENTS

    Nov 1, 2019, 00:00
  • PGI23 COST OF INFLAMMATORY BOWEL DISEASE MANAGEMENT IN THE KINGDOM OF SAUDI ARABIA

    Nov 1, 2019, 00:00
  • PDB39 INSULIN PRICE FLUCTUATION IN THE USA BETWEEN JULY 2017 AND JULY 2019

    Nov 1, 2019, 00:00
  • PCN222 CARFILZOMIB/LENALIDOMIDE/DEXAMETHASONE IN THE SECOND-LINE SETTING FOLLOWED BY DARATUMUMAB/LENALIDOMIDE/DEXAMETHASONE IN THE THIRD-LINE SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE: A COST COMPARISON STUDY FROM A BRAZILIAN PRIVATE H ...

    Nov 1, 2019, 00:00
  • PIN60 COMPARISON OF ANTI-HIV AND ANTI-HCV THERAPY COSTS IN THE CZECH REPUBLIC

    Nov 1, 2019, 00:00
  • Cancer - Clinical Outcomes

    Nov 1, 2019, 00:00
  • PRO44 THE ECONOMIC IMPACT AND HEALTH-RELATED QUALITY OF LIFE OF SPINAL MUSCULAR ATROPHY (SMA). AN ANALYSIS ACROSS THREE EUROPEAN COUNTRIES

    Nov 1, 2019, 00:00
  • PNS35 MULTI-NATIONAL NORDIC PHARMACOEPIDEMIOLOGIC STUDIES: OPPORTUNITIES AND CHALLENGES

    Nov 1, 2019, 00:00
  • PCN500 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES FOR PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA RECEIVING SYSTEMIC THERAPY IN BRAZIL

    Nov 1, 2019, 00:00
  • Drugs Generics - Health Technology Assessment

    Nov 1, 2019, 00:00
  • PCN443 INDIRECT COMPARISON BETWEEN REAL WORLD DATA AND CLINICAL TRIAL IN NON SMALL CELL LUNG CANCER WITH BEVACIZUMAB

    Nov 1, 2019, 00:00
  • PCN50 INDIRECT COMPARISON OF PARP INHIBITORS IN OVARIAN CANCER: NETWORK META-ANALYSIS

    Nov 1, 2019, 00:00
  • PMS59 REAL-WORLD EFFECTIVENESS OF PHYSIOTHERAPY INTERVENTIONS FOR MUSCULOSKELETAL DISORDERS IN NIGERIA

    Nov 1, 2019, 00:00
  • PIN14 HEALTH UTILITY ESTIMATES FOR CONGENITAL CYTOMEGALOVIRUS DISEASE: CONCEPTUAL DESIGN CONSIDERATIONS

    Nov 1, 2019, 00:00
  • Mental Health - Clinical Outcomes

    Nov 1, 2019, 00:00
  • PCN524 EUROPEAN REAL-WORLD TREATMENT PATTERNS OF SYSTEMIC THERAPIES FOR SECOND LINE (2L) HEPATOCELLULAR CARCINOMA (HCC) PATIENTS WHO PREVIOUSLY RECEIVED SORAFENIB

    Nov 1, 2019, 00:00
  • Urinary/Kidney Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00
  • PRO3 TREATMENT PATTERNS AND OUTCOMES ASSOCIATED WITH THE USE OF PONATINIB IN CLINICAL PRACTICE: A QUALITATIVE SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2019, 00:00
  • PIT10 THE INCREMENTAL COST OF TRAUMATIC BRAIN INJURY DURING THE FIRST YEAR AFTER A ROAD TRAFFIC ACCIDENT IN BELGIUM

    Nov 1, 2019, 00:00
  • PRO46 EMICIZUMAB PROPHYLAXIS IS A COST-SAVING OPTION FOR HEMOPHILIA A PATIENTS WITH INHIBITORS IN KOREA: A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2019, 00:00
  • PCN370 IMPROVING PATIENT ACCESS TO INNOVATIVE MEDICATIONS WHILE PROTECTING PUBLIC BUDGETS SUSTAINABILITY: AN ALTERNATIVE GO TO MARKET AND PRICING FRAMEWORK TO ENABLE VALUE CO-CREATION BETWEEN PHARMAS AND PAYERS

    Nov 1, 2019, 00:00
  • PMU52 ANALYSIS OF THE REIMBURSEMENT DECISIONS MADE BY THE INTERMINISTERIAL PRICE COMMISSION FOR MEDICINES IN SPAIN

    Nov 1, 2019, 00:00
  • PCN436 RESPONSIVENESS OF THE EQ-5D-5L AND EORTC QLU-C10D IN CANCER PATIENTS

    Nov 1, 2019, 00:00
  • PGI3 DEPRESCRIBING OF LONG TERM UTILIZATION OF H2 RECEPTOR ANTAGONISTS AND PROTON PUMP INHIBITORS BASED ON ENDOSCOPIC ANALYSIS

    Nov 1, 2019, 00:00
  • PCV152 SELF-ASSESSED FUNCTIONAL CLASS, QUALITY OF LIFE AND HEALTHCARE RESOURCE CONSUMPTION IN PORTUGUESE HEART FAILURE PATIENTS: AN ANALYSIS OF THE PRIME STUDY

    Nov 1, 2019, 00:00
  • PCV99 UNDERSTANDING POST DISCHARGE MANAGEMENT AFTER AN ACUTE MYOCARDIAL INFARCTION IN ITALY: REGIONAL PATHWAYS AND OUTCOME INDEX

    Nov 1, 2019, 00:00
  • PDB16 ASSESSMENT OF COST-EFFECTIVENESS OF A 0.2 ΜCG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN PATIENTS WITH CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN AN EYE WITH CATARACT

    Nov 1, 2019, 00:00
  • PNS176 COMPARISON OF HOSPITAL BED NUMBERS IN EUROPEAN OECD COUNTRIES WITH BISMARCK- AND BEVERIDGE HEALTH CARE MODELS

    Nov 1, 2019, 00:00
  • PCN43 NEW CERVICAL CANCER SCREENING POLICY IN GERMANY - WHAT IS THE IMPACT ON THE BENEFIT-HARM BALANCE?

    Nov 1, 2019, 00:00
  • PCN244 BUDGETARY IMPACT OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Nov 1, 2019, 00:00
  • PCN143 COMPARISON OF ADVERSE EVENT COSTS OF NIVOLUMAB+IPILIMUMAB VERSUS SUNITINIB FOR PREVIOUSLY UNTREATED INTERMEDIATE-/POOR-RISK ADVANCED RENAL CELL CARCINOMA IN PORTUGAL

    Nov 1, 2019, 00:00
  • PDG18 COST-EFFECTIVENESS ANALYSIS OF INTRAVITREAL AFLIBERCEPT IN TREATING NAMD IN CHINA

    Nov 1, 2019, 00:00
  • PCN487 COST OF PROSTATE CANCER AND QUALITY OF LIFE IN EGYPT - A PATIENT PERSPECTIVE STUDY

    Nov 1, 2019, 00:00
  • PCN153 OVERVIEW OF ECONOMIC EVALUATIONS OF ONCOLOGY PRODUCTS WITH A FOCUS ON THE KEY CHALLENGES ACROSS, UNITED KINGDOM, FRANCE AND CANADA

    Nov 1, 2019, 00:00
  • PR4 TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM - VERSION 1.4): CEILING AND FLOOR EFFECTS, RELIABILITY AND CONSTRUCT VALIDITY

    Nov 1, 2019, 00:00
  • PMH13 SYSTEMATIC REVIEW OF UTILITY VALUES USED IN THE PHARMACOECONOMIC EVALUATIONS FOR SCHIZOPHRENIA: IMPLICATIONS ON COST-EFFECTIVENESS RESULTS

    Nov 1, 2019, 00:00
  • Musculoskeletal Disorders - Health Service Delivery Process of Care

    Nov 1, 2019, 00:00
  • PPM6 HEALTH ECONOMICS MODEL OF FOUNDATIONONE CDX® IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN TURKEY

    Nov 1, 2019, 00:00
  • PCN284 PRESCRIBING TRENDS ACROSS EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS IN NON-SMALL CELL LUNG CANCER IN IRELAND

    Nov 1, 2019, 00:00
  • PNS290 EVIDENCE-BASED VALUE FRAMEWORK FOR THE EVALUATION OF CLINICAL PHARMACY SERVICES

    Nov 1, 2019, 00:00
  • PBI89 PHARMACOUTILIZATION OF BIOLOGICAL DRUGS IN PATIENTS AFFECTED BY PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN AN ITALIAN REAL-WORLD SETTING

    Nov 1, 2019, 00:00
  • PRS48 UNLOCKING THE ACCESS CHALLENGES TO COPD

    Nov 1, 2019, 00:00
  • «
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40 (current)
  • »